• About us
• Contact

Advertisement

Organisation › Details

Symphogen A/S

Symphogen is a private biopharmaceutical company leading the field of recombinant antibody mixtures for therapeutic use in oncology. Symphogen is dedicated to bringing truly innovative oncology products to the market, creating optimally selected antibody mixtures that address multiple oncology targets in a single drug product. The company has collaborations for the development of antibody therapeutics in the infectious disease area with Genentech, and in immuno-oncology with Shire. Symphogen employs 125 people, has offices in Denmark and New Jersey, US and its investors include Essex Woodlands Health Ventures, Novo A/S, PKA, Sunstone Capital, Gilde Healthcare Partners, Danica Pension, Takeda Ventures, Inc., and Genentech. *

 

	Start	2005-01-27 existent
	Group	Servier (Group)
	Industry	polyclonal antibody
	Street	Elektrovej Building 375
	City	2800 Lyngby
	Tel	+45-4526-5050
		Address record changed: 2020-12-02
Basic data	Employees	D: 101 to 500 (2016-09-15)
	Currency	DKK
	Annual sales	43,472,000 (revenue (2006) 2006-12-31)
	Profit	-76,989,000 (2006-12-31)
	Cash	70,000,000 (2015-01-29)
		* Document for »About Section«:
		Record changed: 2024-02-12

Advertisement

More documents for Servier (Group)

• [1] Thermo Fisher Scientific Inc.. (10/29/18). "Press Release: Thermo Fisher Scientific Announces Collaboration to Simplify Analysis of Complex Therapeutic Proteins". Sunnyvale, CA....
• [2] GeNeuro S.A.. (9/18/18). "Press Release: GeNeuro Regains Worldwide Rights ex US and Japan to GNbAC1 in Multiple Sclerosis from Servier". Paris & Geneva....
• [3] GeNeuro S.A.. (12/21/17). "Press Release: GeNeuro To Receive €12 Million Milestone Payment from Servier for Final Patient Visit in GNbAC1 CHANGE-MS Phase 2b Study". Geneva....
• [4] Servier. (11/2/17). "Press Release: Servier Germany to Co-promote Novartis’ Blockbuster Entresto"....
• [5] Servier. (2/14/17). "Press Release: Servier and GAIA Extend Their Partnership to Provide Patients around the World with Deprexis, an Internet-based Cognitive Behavioral Therapy for Depression". Suresnes & Hamburg....
• [6] Pieris Pharmaceuticals, Inc.. (1/5/17). "Press Release: Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance". Boston, MA & Suresnes....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.